ABEOME CORPORATION
Transgenic mouse models and neutralizing antibodies targeting PCSK9
- Sector
- Biotech
- Headquarters
- ATHENS, GA
- Latest Form D
- Feb 2014
- Total capital
- $3M
- Federal grants
- $3M
- 3 awards · 2016–2017
- Rank in peer group#340 of 514
- Private capital raised
- None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 1
- 8 pending · first 2022
- Rank in peer group#186 of 514
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · Novel Therapeutic Approach to Hypercholesterolemia Using Anti-PCSK9 Selected Immune Repertoires$673K
- Federal grantHealth and Human S · Phase II · Novel Therapeutic Approach to Hypercholesterolemia Using Anti PCSK Selected Immune Repertoires$1.5M
- Federal grantHealth and Human S · Phase II · Novel Therapeutic Approach to Hypercholesterolemia Using Anti-PCSK9 Selected Immune Repertoires$810K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
1 record has no date or no amount, so it isn’t placed on the timeline.
Standing among 514 peers
Line = medianBiotech · Molecule
- Federal grantsBelow median
- Granted patents#186 · top 36%
- Linked publications#77 · top 15%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Richard A ShimketsResearcherExecutive OfficerLinked by $1.5M in grants as PI
What it has protected
USPTO · 1 granted of 9- GrantedNeutralizing Monoclonal Antibodies To IL-25 And Uses ThereofUSPTOUS 11,492,397
- PendingPD-L1-BINDING Proteins Comprising Shiga Toxin A Subunit ScaffoldsUSPTOApplication 62970610
- PendingPD-L1-BINDING Proteins Comprising Shiga Toxin A Subunit ScaffoldsUSPTOApplication 62933197
Show all 9 patent records
- Neutralizing Monoclonal Antibodies To IL-25 And Uses ThereofNov 8, 2022 · US 11,492,397Granted
- PD-L1-BINDING Proteins Comprising Shiga Toxin A Subunit ScaffoldsApplication 62970610Pending
- PD-L1-BINDING Proteins Comprising Shiga Toxin A Subunit ScaffoldsApplication 62933197Pending
- PD-L1-BINDING Proteins Comprising Shiga Toxin A Subunit ScaffoldsApplication 62902243Pending
- High Affinity Neutralizing Monoclonal Antibodies To Programmed Death Ligand 1 (PD-L1) And Uses ThereofApplication PCTUS2019022971Pending
- High Affinity Neutralizing Monoclonal Antibodies to Programmed Death Ligand 1 (PD-L1) and uses thereofApplication 62644832Pending
- Neutralizing Monoclonal Antibodies To IL-25 And Uses ThereofApplication PCTUS2017021578Pending
- PD-L1-BINDING Molecules Comprising Shiga Toxin A Subunit ScaffoldsApplication 63041288Pending
- Antibody Generation From Plasmacytoma-prone Transgenic AnimalsApplication PCTUS2012033797Pending
Recent research by its founders
- IL-25 blockade augments antiviral immunity during respiratory virus infection202230 cites
- Neutralization of <i>Plasmodium falciparum</i> Merozoites by Antibodies against PfRH52013156 cites
- Inhibition of in vitro and in vivo T cell responses by recombinant human Tim-1 extracellular domain proteins200621 cites
Related companies, and why
- RNA THERAPEUTICS INC.Similar federal contract value in Biotech · null in contracts
- APERTURE THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
- Converge Bio Inc.Similar federal contract value in Biotech · null in contracts
- CELLECTAR BIOSCIENCES, INC.Similar federal contract value in Biotech · null in contracts
- PAVAJ VASCULAR CORPORATIONSimilar federal contract value in Biotech · null in contracts
- CELLERGY PHARMASimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .